China (Mainland)
Ledipasvir-factory CAS NO.1256388-51-8
- Min.Order: 0 Metric Ton
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Ledipasvir-factory
- 1256388-51-8
- Ledipasvir API
Quick Details
- ProName: Ledipasvir-factory
- CasNo: 1256388-51-8
- Molecular Formula: C49H54F2N8O6
- Appearance: white powder
- Application: Hepatitis c virus (HCV) API CAS NO.12...
- ProductionCapacity: Metric Ton/Day
- Purity: 99%
- LimitNum: 0 Metric Ton
Superiority
GS 588;GS5885;GS 5885;GS-5885;Ledipasvir;Leidipawei;gs-5885/gs5885;HY-15602 (GS-5885;GS-5885/Ledipasvir;Ledipasvir / GS 5885
| CBNumber: | CB52666650 |
factory
Details
Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.[1] After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C.[2][3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.
Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analog inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1.[4][5] The sofosbuvir/ledipasvir coformulation is being tested with and without ribavirin. In February 2014 Gilead has filed for United States Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment, without interferon and ribavirin.[6]
On October 10, 2014 the FDA approved the combination product ledipasvir/sofosbuvir called Harvoni.[7]